Pioneering medicine with the power
to prevent

Siolta Therapeutics is a clinical-stage biotech company on a mission to alleviate the suffering of millions impacted by chronic inflammatory diseases through novel microbiome-based medicines. We leverage our deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases. Our blended expertise from microbiology, immunology, and bioinformatics supports the development of a multifaceted platform, integrating ecosystems approaches and precision medicine concepts to advance the future of medicine. Currently focused on the clinical development of our lead product for the prevention and treatment of allergic asthma, Siolta’s holistic, microbiome-based strategy represents a new frontier in the pursuit of tailored, clinically differentiated microbial therapeutics.

See Our Science



From Irish origins, Siolta is a Gaelic word for “seeds.” Our microbial therapeutics are reseeding the depleted gut microbiome with naturally occurring bacteria, essential for a healthy immune system.

Our Mission

To develop microbiome-based therapeutics and diagnostics aimed at the prevention and treatment of chronic inflammatory diseases,
beginning with asthma.

Susan Lynch (University of California at San Francisco, or UCSF) and Nikole Kimes (Siolta, formerly UCSF) co-founded Siolta Therapeutics in partnership with Samir Kaul (Khosla Ventures) in 2016. Our combined expertise from the venture-backed start-up world with our strong scientific background and know-how support the realization of our vision in a streamlined manner. Since our inception, we have built an exceptional team, moved rapidly through early preclinical development into clinical trials, while advancing our scientific, regulatory, and clinical goals along the way.

Meet Our Team